FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Lennard

Research Profile

Chemicals & Drugs

Anatomy

Microsomes, Liver

Phenomena

Co-author Network

Publications

TOP 3
Mohammad-Reza Shiran; Geoffrey T Tucker; Nicholas Seivewright; Mohammad-Zafar Iqbal; Olawale Lagundoye; Martin S Lennard; Amin Rostami-Hodjegan
Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.
S J C Davies; A A Westin; I Castberg; Glyn Lewis; Martin S Lennard; S Taylor; O Spigset
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.
Cyrus Ghobadi; S A K Amer; Hany Lashen; Martin S Lennard; William L Ledger; Amin Rostami-Hodjegan
Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Lennard (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Mohammad-Reza Shiran; Geoffrey T Tucker; Nicholas Seivewright; Mohammad-Zafar Iqbal; Olawale Lagundoye; Martin S Lennard; Amin Rostami-Hodjegan
Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.
Journal of clinical psychopharmacology 2012;32(5):666-71.
2010: S J C Davies; A A Westin; I Castberg; Glyn Lewis; Martin S Lennard; S Taylor; O Spigset
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.
Acta psychiatrica Scandinavica 2010;122(6):444-53.
2009: Cyrus Ghobadi; S A K Amer; Hany Lashen; Martin S Lennard; William L Ledger; Amin Rostami-Hodjegan
Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate.
Fertility and sterility 2009;91(4):1135-40.
2009: Cyrus Ghobadi; Nahid Mirhosseini; Mohammad Reza Shiran; Ali Moghadamnia; Martin S Lennard; William L Ledger; Amin Rostami-Hodjegan
Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease.
Journal of clinical pharmacology 2009;49(2):147-54.
2009: Mohammad Reza Shiran; Martin S Lennard; Muhammad Z Iqbal; Olawale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
British journal of clinical pharmacology 2009;67(1):29-37.
2008: Cyrus Ghobadi; Anne Gregory; H Kim Crewe; Amin Rostami-Hodjegan; Martin S Lennard
CYP2D6 is primarily responsible for the metabolism of clomiphene.
Drug metabolism and pharmacokinetics 2008;23(2):101-5.
2007: Linh M Van; Judith A Hargreaves; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2007;32(1):8-16.
2007: Gemma L Dickinson; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
British journal of clinical pharmacology 2007;64(1):14-26.
2007: Simon J C Davies; Martin S Lennard; Parviz Ghahramani; Peter Pratt; Andrea Robertson; John P Potokar
PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.
Journal of psychopharmacology (Oxford, England) 2007;21(2):153-60.
2007: Cyrus Ghobadi; Tien Huu Nguyen; Martin S Lennard; S A K Amer; Amin Rostami-Hodjegan; William L Ledger
Evaluation of an existing nomogram for predicting the response to clomiphene citrate.
Fertility and sterility 2007;87(3):597-602.
2007: H Kim Crewe; Cyrus Ghobadi; A Gregory; Amin Rostami-Hodjegan; Martin S Lennard
Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;847(2):296-9.
2007: Gemma L Dickinson; Saeed Rezaee; Nicholas J Proctor; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Journal of clinical pharmacology 2007;47(2):175-86.
2006: Tien Huu Nguyen; Martin S Lennard; Cyrus Ghobadi; Amin Rostami-Hodjegan; William L Ledger
Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
Journal of assisted reproduction and genetics 2006;23(11-12):427-31.
2006: Linh M Van; Amir Heydari; Jiansong Yang; Judith A Hargreaves; Karen Rowland Yeo; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Journal of psychopharmacology (Oxford, England) 2006;20(6):834-41.
2006: G L Dickinson; Amin Rostami-Hodjegan; Olawale Lagundoye; Nicholas Seivewright; P Pratt; Martin S Lennard
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK.
Journal of clinical pharmacy and therapeutics 2006;31(5):477-84.
2006: Richard Walker; Robert J Flanagan; Martin S Lennard; Graham A Mills; Valerie Walker
Solid-phase microextraction: investigation of the metabolism of substances that may be abused by inhalation.
Journal of chromatographic science 2006;44(7):387-93.
2006: Eleanor Row; SA Brown; Andrew V Stachulski; Martin S Lennard
Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4.
Bioorganic & medicinal chemistry 2006;14(11):3865-71.
2006: Eleanor Row; SA Brown; Andrew V Stachulski; Martin S Lennard
Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4.
Organic & biomolecular chemistry 2006;4(8):1604-10.
2006: F Ghanbari; Karen Rowland Yeo; JC Bloomer; S E Clarke; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.
Current drug metabolism 2006;7(3):315-34.
2006: Eleanor Row; SA Brown; Andrew V Stachulski; Martin S Lennard
Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(2):324-30.
2005: Lisa M Notley; K H Crewe; P J Taylor; Martin S Lennard; Elizabeth M J Gillam
Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.
Chemical research in toxicology 2005;18(10):1611-8.
2005: Mohammad Reza Shiran; Mohammad Hassanzadeh-Khayyat; Muhammad Z Iqbal; Olawale Lagundoye; Nicholas Seivewright; Martin S Lennard; Geoffrey T Tucker; Amin Rostami-Hodjegan
Can saliva replace plasma for the monitoring of methadone?
Therapeutic drug monitoring 2005;27(5):580-6.
2004: H Kim Crewe; Martin S Lennard; Geoffrey T Tucker; F R Woods; R E Haddock
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992.
British journal of clinical pharmacology 2004;58(7):S744-7; discussion 748-50.
2004: Amir Heydari; Karen Rowland Yeo; Martin S Lennard; S Wynne Ellis; Geoffrey T Tucker; Amin Rostami-Hodjegan
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(11):1213-7.
2004: Amin Rostami-Hodjegan; Martin S Lennard; Geoffrey T Tucker; William L Ledger
Monitoring plasma concentrations to individualize treatment with clomiphene citrate.
Fertility and sterility 2004;81(5):1187-93.
2004: S J C Davies; S Eayrs; P Pratt; Martin S Lennard
Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.
British journal of clinical pharmacology 2004;57(4):464-72.
2004: Amin Rostami-Hodjegan; Ajmal M Amin; Edgar P Spencer; Martin S Lennard; Geoffrey T Tucker; Robert J Flanagan
Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.
Journal of clinical psychopharmacology 2004;24(1):70-8.
2003: Mohammad Reza Shiran; Joey Chowdry; Amin Rostami-Hodjegan; S Wynne Ellis; Martin S Lennard; Muhammad Z Iqbal; Olawale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.
British journal of clinical pharmacology 2003;56(2):220-4.
2003: M J Graham; A R Bell; H Kim Crewe; C L Moorcraft; L Walker; E F Whittaker; Martin S Lennard
mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(3):225-37.
2003: Mohammad Reza Shiran; A Gregory; Amin Rostami-Hodjegan; Geoffrey T Tucker; Martin S Lennard
Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;783(1):303-7.
2002: H Kim Crewe; Lisa M Notley; Rebecca M Wunsch; Martin S Lennard; Elizabeth M J Gillam
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(8):869-74.
2001: GP Hayhurst; Jacky Harlow; Joey Chowdry; E Gross; E Hilton; Martin S Lennard; Geoffrey T Tucker; S Wynne Ellis
Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
The Biochemical journal 2001;355(Pt 2):373-9.
2000: J T Forsyth; R A Grünewald; Amin Rostami-Hodjegan; Martin S Lennard; HJ Sagar; Geoffrey T Tucker
Parkinson's disease and CYP1A2 activity.
British journal of clinical pharmacology 2000;50(4):303-9.
2000: T Coleman; E F Spellman; Amin Rostami-Hodjegan; Martin S Lennard; Geoffrey T Tucker
The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(9):1094-9.
2000: T Lightfoot; S Wynne Ellis; J Mahling; MJ Ackland; F E Blaney; GJ Bijloo; Marcel J de Groot; Nico P E Vermeulen; G M Blackburn; Martin S Lennard; Geoffrey T Tucker
Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(3):219-33.
2000: S Wynne Ellis; GP Hayhurst; T Lightfoot; G Smith; Jacky Harlow; Karen Rowland Yeo; C Larsson; J Mahling; C K Lim; C R Wolf; M G Blackburn; Martin S Lennard; Geoffrey T Tucker
Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
The Biochemical journal 2000;345 Pt 3():565-71.
1999: R Abdul Manap; CE Wright; A Gregory; Amin Rostami-Hodjegan; S T Meller; Gary R Kelm; Martin S Lennard; Geoffrey T Tucker; AH Morice
The antitussive effect of dextromethorphan in relation to CYP2D6 activity.
British journal of clinical pharmacology 1999;48(3):382-7.
1998: Amin Rostami-Hodjegan; Martin S Lennard; H F Woods; Geoffrey T Tucker
Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.
Pharmacogenetics 1998;8(3):227-38.
1998: O O Simooya; G Sijumbil; Martin S Lennard; Geoffrey T Tucker
Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
British journal of clinical pharmacology 1998;45(3):315-7.
1997: L Y Lin; E W Di Stefano; Debra A Schmitz; L Hsu; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker; Arthur K Cho
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(9):1059-64.
1997: Parviz Ghahramani; S Wynne Ellis; Martin S Lennard; Lawrence E Ramsay; Geoffrey T Tucker
Cytochromes P450 mediating the N-demethylation of amitriptyline.
British journal of clinical pharmacology 1997;43(2):137-44.
1997: H Kim Crewe; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
Biochemical pharmacology 1997;53(2):171-8.
1996: Parviz Ghahramani; Martin S Lennard
Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;685(2):307-13.
1996: K Rowland; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker
Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
British journal of clinical pharmacology 1996;42(3):390-3.
1996: R Mackman; R A Tschirret-Guth; G Smith; G P Hayhurst; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker; C R Wolf; Paul R. Ortiz de Montellano
Active-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants.
Archives of biochemistry and biophysics 1996;331(1):134-40.
1996: S Wynne Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; Martin S Lennard; C R Wolf; Geoffrey T Tucker
Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
The Biochemical journal 1996;316 ( Pt 2)():647-54.
1996: T Coleman; S Wynne Ellis; I J Martin; Martin S Lennard; Geoffrey T Tucker
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
The Journal of pharmacology and experimental therapeutics 1996;277(2):685-90.
1995: S Wynne Ellis; G P Hayhurst; G Smith; T Lightfoot; M M Wong; A P Simula; M J Ackland; M J Sternberg; Martin S Lennard; Geoffrey T Tucker
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6.
The Journal of biological chemistry 1995;270(49):29055-8.
1995: Michael S Ching; C L Blake; Hany Ghabrial; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker; R A Smallwood
Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Biochemical pharmacology 1995;50(6):833-7.
1994: M L Williams; Martin S Lennard; I J Martin; G T Tucker
Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450.
Carcinogenesis 1994;15(12):2733-8.
1994: K Rowland; Wilfred W Yeo; S Wynne Ellis; I G Chadwick; IU Haq; Martin S Lennard; P R Jackson; L E Ramsay; Geoffrey T Tucker
Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
British journal of clinical pharmacology 1994;38(1):9-14.
1994: H M Barham; Martin S Lennard; Geoffrey T Tucker
An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Biochemical pharmacology 1994;47(8):1295-307.
1994: Geoffrey T Tucker; Martin S Lennard; S Wynne Ellis; H F Woods; Arthur K Cho; L Y Lin; A Hiratsuka; Debra A Schmitz; T Y Chu
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).
Biochemical pharmacology 1994;47(7):1151-6.
1993: A R Watts; Martin S Lennard; S L Mason; Geoffrey T Tucker; H F Woods
Beeturia and the biological fate of beetroot pigments.
Pharmacogenetics 1993;3(6):302-11.
1993: O O Simooya; E Njunju; A R Hodjegan; Martin S Lennard; Geoffrey T Tucker
Debrisoquine and metoprolol oxidation in Zambians: a population study.
Pharmacogenetics 1993;3(4):205-8.
1992: H K Crewe; Martin S Lennard; Geoffrey T Tucker; F R Woods; R E Haddock
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
British journal of clinical pharmacology 1992;34(3):262-5.
1992: S Wynne Ellis; Michael S Ching; P F Watson; C J Henderson; A P Simula; Martin S Lennard; Geoffrey T Tucker; H F Woods
Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Biochemical pharmacology 1992;44(4):617-20.
1992: J C Bloomer; F R Woods; R E Haddock; Martin S Lennard; Geoffrey T Tucker
The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
British journal of clinical pharmacology 1992;33(5):521-3.
1992: Martin S Lennard; A O Iyun; P R Jackson; Geoffrey T Tucker; H F Woods
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
Pharmacogenetics 1992;2(2):89-92.
1991: E A Blankson; S Wynne Ellis; Martin S Lennard; Geoffrey T Tucker; K Rogers
The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
Biochemical pharmacology 1991;42 Suppl():S209-12.
1991: J M Pepper; Martin S Lennard; Geoffrey T Tucker; H F Woods
Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol.
Pharmacogenetics 1991;1(2):119-22.
1991: M Adams; Martin S Lennard; S V Otton; Geoffrey T Tucker; H F Woods
Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.
Biochemical pharmacology 1991;42(4):947-9.
1991: M S Ching; Martin S Lennard; Geoffrey T Tucker; H F Woods; D E Kelly; S L Kelly
The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae.
Biochemical pharmacology 1991;42(4):753-8.
1991: Martin S Lennard
Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.
British journal of clinical pharmacology 1991;31(6):623-5.
1991: R V Lewis; L E Ramsay; P R Jackson; Wilfred W Yeo; Martin S Lennard; Geoffrey T Tucker
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
British journal of clinical pharmacology 1991;31(4):391-8.
1990: S V Otton; E M Gillam; Martin S Lennard; Geoffrey T Tucker; H F Woods
Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.
British journal of clinical pharmacology 1990;30(5):751-60.
1990: Martin S Lennard
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Pharmacology & toxicology 1990;67(4):273-83.
1990: D L Lancaster; R A Adio; K K Tai; O O Simooya; G D Broadhead; Geoffrey T Tucker; Martin S Lennard
Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.
The Journal of pharmacy and pharmacology 1990;42(4):267-71.
1989: M S Ching; Martin S Lennard; A Gregory; Geoffrey T Tucker
Measurement of underivatised metoprolol enantiomers in human plasma by high-performance liquid chromatography with a chiral stationary phase.
Journal of chromatography 1989;497():313-8.
1989: C Q Morris; Geoffrey T Tucker; H K Crewe; J R Harlow; H F Woods; Martin S Lennard
Histamine inhibition of mixed function oxidase activity in rat and human liver microsomes and in the isolated perfused rat liver.
Biochemical pharmacology 1989;38(16):2639-44.
1989: Martin S Lennard; Geoffrey T Tucker; H F Woods; J H Silas; A O Iyun
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
British journal of clinical pharmacology 1989;27(5):613-6.
1989: Martin S Lennard; R V Lewis; L A Brawn; Geoffrey T Tucker; L E Ramsay; P R Jackson; H F Woods
Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
British journal of clinical pharmacology 1989;27(4):429-34.
1989: Martin S Lennard
Metoprolol-induced hepatitis: is the rate of oxidation related to drug-induced hepatotoxicity?
Hepatology (Baltimore, Md.) 1989;9(1):163-4.
1988: S V Otton; H K Crewe; Martin S Lennard; Geoffrey T Tucker; H F Woods
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
The Journal of pharmacology and experimental therapeutics 1988;247(1):242-7.
1988: Martin S Lennard; J C McGourty; J H Silas
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
British journal of clinical pharmacology 1988;25(2):276-8.
1988: Martin S Lennard; Geoffrey T Tucker; H F Woods; A O Iyun; M Eichelbaum
Stereoselective 4-hydroxylation of debrisoquine in Nigerians.
Biochemical pharmacology 1988;37(1):97-8.
1986: A O Iyun; Martin S Lennard; Geoffrey T Tucker; H F Woods
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.
Clinical pharmacology and therapeutics 1986;40(4):387-94.
1986: Martin S Lennard; H K Crewe; Geoffrey T Tucker; H F Woods
Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs.
Biochemical pharmacology 1986;35(16):2757-61.
1986: Martin S Lennard; H K Crewe; Geoffrey T Tucker; H F Woods
Histamine: an inhibitor of cytochrome P-450-catalysed drug metabolism.
Biochemical pharmacology 1986;35(15):2459-60.
1985: J C McGourty; J H Silas; Martin S Lennard; Geoffrey T Tucker; H F Woods
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
British journal of clinical pharmacology 1985;20(6):555-66.
1985: J H Silas; J C McGourty; Martin S Lennard; Geoffrey T Tucker; H F Woods
Polymorphic metabolism of metoprolol: clinical studies.
European journal of clinical pharmacology 1985;28 Suppl():85-8.